What is the latest price of Opicapone in 2024?

Opicapone (Opicapone) is a once-daily, oral, peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment to Levodopa/Carbidopa for patients with Parkinson's disease (PD) experiencing "off" episodes.

The FDA's approval of Opicapone is supported by data from two pivotal trials in patients with Parkinson's disease and end-dose motor fluctuations (BIPARK-I and II), which demonstrated acceptable tolerability profiles and efficacy in reducing discontinuation time in adult patients with Parkinson's disease and end-dose motor fluctuations. The most common side effects were dyskinesia (difficulty controlling movements), constipation, elevated blood creatine kinase, hypotension/syncope, and weight loss. These studies also led to the approval of Opicapone in other countries such as the European Union, the United Kingdom, and Australia, providing more treatment options for patients.

The drug Opicapone is not yet on the market in China, so it is not yet included in medical insurance. This undoubtedly increases the financial burden for patients who need this drug. In the European market, the original drug of Opicapone is already on the market. Its specification is 50mg*90 pills per box, and the price is about more than 4,000 yuan (the price may fluctuate due to the exchange rate). Although demand exists, there are currently no generic versions of Opicapone on the market, leaving patients with relatively limited treatment options. It is hoped that more solutions will emerge in the future to reduce the burden on patients.